Immatics N.V. IMTX
6.52 USD -0.17 (-2.54%)
At closeNov 12, 2026, 5:31 PM EST
6.52 0.00 0.00%
After hours · Nov 12, 5:31 PM ET
6.34 Day range 6.89
6.18 52-week range 11.87
- YTD
- -37.90%
- 1 year
- -38.89%
News
benzinga.com Immuneering Enters Into Clinical Trial Collaboration And Supply Agreement To Supply Investigational MEK Inhibitor, Atebimetinib, For Two Astellas-Sponsored Studies Targeting Subset Of Pancreatic Cancer Patients - Collaboration aligns with Immuneering’s expanding strategy to provide a broad population of cancer patients with a wide set of treatment options -- Represents Immuneering’s fourth agreement with a…
zacks.com Immatics (IMTX) Reports Q3 Loss, Lags Revenue Estimates Immatics (IMTX) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $0.49 per share a year ago.
benzinga.com Immatics Q3 EPS $(0.58) Misses $(0.49) Estimate, Sales $7.968M Miss $10.230M Estimate Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.49) by 18.37 percent. This is a 18.37 percent decrease over losses of $(0.49)…
globenewswire.com Immatics Announces Third Quarter 2026 Financial Results and Business Update Houston, Texas and Tuebingen, Germany, November 10, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage…
zacks.com Immatics (IMTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Immatics (IMTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.- benzinga.com Reported Saturday, Immatics Reports IMA203CD8 Cell Therapy 51% ORR, 41% cORR Across Multiple Solid Tumors With Manageable Safety; IMA402 Bispecific Shows 32% cORR In PRAME-High Melanoma, Favorable Safety Profile IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profileIMA402 achieved a cORR of 32%, 12.5 months median DOR and…
globenewswire.com Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting Houston, Texas and Tuebingen, Germany, October 24, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage…
benzinga.com This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Analysts initiated coverage on VYLR, IMTX, ENTG, SLGL and SPTX, assigning Neutral, Buy or Overweight ratings and price targets.
benzinga.com Stifel Initiates Coverage On Immatics with Buy Rating, Announces Price Target of $15 Stifel analyst Laura Prendergast initiates coverage on Immatics (NASDAQ:IMTX) with a Buy rating and announces Price Target of $15.
defenseworld.net Immatics (NASDAQ:IMTX) vs. Kyntra Bio (NASDAQ:KYNB) Financial Contrast Kyntra Bio (NASDAQ: KYNB - Get Free Report) and Immatics (NASDAQ: IMTX - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two…
defenseworld.net Immatics (NASDAQ:IMTX) Reaches New 1-Year Low – Here’s Why Immatics N.V. (NASDAQ: IMTX - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Friday. The stock traded as low as $7.02 and last traded at $7.37, with a volume of…
defenseworld.net Immatics (NASDAQ:IMTX) Sees Strong Trading Volume – Still a Buy? Immatics N.V. (NASDAQ: IMTX - Get Free Report) shares saw unusually-strong trading volume on Wednesday. 434,954 shares changed hands during trading, a decline of 11% from the previous session's…
seekingalpha.com Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma Immatics N.V. is rated "Buy," downgraded from "Strong Buy," due to partial partnership termination and pivotal trial dependency. IMTX's investment thesis centers on anzu-cel [IMA203], a…
benzinga.com Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.
benzinga.com Immatics Announces $150M Underwritten Offering Of Ordinary Shares And Pre-Funded Warrants Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company"))), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, announced
globenewswire.com Immatics Announces $150 Million Underwritten Offering Houston, Texas and Tuebingen, Germany, August 25, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage…- benzinga.com Immatics Q2 EPS $(0.53) Misses $(0.43) Estimate, Sales $10.630M Miss $14.590M Estimate Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.43) by 23.26 percent. This is a 19.7 percent increase over losses of $(0.66)…
globenewswire.com Immatics Announces Second Quarter 2026 Financial Results and Business Update Houston, Texas and Tuebingen, Germany, August 18, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage…
defenseworld.net Analysts Set Immatics N.V. (NASDAQ:IMTX) Target Price at $20.80 Shares of Immatics N.V. (NASDAQ: IMTX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are presently covering the company,…
globenewswire.com Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 Houston, Texas and Tuebingen, Germany, July 17, 2026 - Immatics N. V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage…
seekingalpha.com Immatics: PRAME Is Becoming More Than A Single-Asset Story Immatics is evolving into a PRAME-focused oncology platform with three monetization paths, not just a single-asset cell therapy play. IMTX's lead asset, anzu-cel, is in Phase 3 for advanced melanoma,…
benzinga.com Immatics Announces Extended Data From Phaseb Clinicla Trial Evaluating Anzu-Cel PRAME TCR T-Cell Therapy In Heavily Pretreated Patients With Advanced Melanoma At ASCO Annual Meeting One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, deep and durable systemic anti-tumor activity in metastatic PD-1 relapsed cutaneous melanoma and…
globenewswire.com Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, deep and durable systemic anti-tumor activity in metastatic PD-1 relapsed cutaneous melanoma and…
globenewswire.com Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancer In head and neck…
globenewswire.com Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer…
zacks.com Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates Immatics (IMTX) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.35 per share a year ago.
benzinga.com Immatics Q1 EPS $(0.50) Misses $(0.42) Estimate, Sales $8.914M Miss $14.590M Estimate Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.42) by 19.05 percent. This is a 42.86 percent decrease over losses of $(0.35)…- benzinga.com Immatics Announces Its Abstract Regarding Pediatric Participant Treatment With PRAME-Directed Cell Therapy Using Its PRAME T-Cell Receptor Accpected For Poster Presentation At American Association For Cancer Research Annual Meeting 2026 Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today…
benzinga.com Immatics Earnings Report: Q4 Overview - benzinga.com Immatics Q4 EPS $(0.34) Beats $(0.48) Estimate, Sales $23.005M Beat $12.180M Estimate Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.48) by 29.17 percent. This is a 170.83 percent decrease over earnings of $0.48…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Fabrinet, Adecoagro And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.- benzinga.com Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings…
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 807 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 90 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's session, 454 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 671 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 368 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 348 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's trading, 505 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 313 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 Penny Stocks
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 88 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Highs On Wednesday Wednesday morning saw 162 companies set new 52-week highs.- benzinga.com 38 Stocks Moving in Thursday's Pre-Market Session Gainers Orbital Energy Group, Inc. (NASDAQ: OEG) shares rose 132.3% to $1.94 in pre-market trading after surging more than 36% on Wednesday.
- benzinga.com Defiance NextGen SPAC IPO ETF Launches: What Investors Need To Know An ETF based on special purpose acquisition companies that trades on a U.S. exchange is now available to investors for the first time.